{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-26-000097","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2026-08-05T10:31:36+00:00","discovered_at":"2026-08-05T10:35:10.606177+00:00","generated_at":"2026-08-05T10:35:51.729472+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Recursion Pharmaceuticals Reports Q2 2026 Results; Genentech Options First Neuroscience Target","bullets":["Genentech exercised first Validated Target Option under neuroscience collaboration, advancing a previously unexplored target into early discovery program.","REC-4881 Phase 2 FAP data to be presented at CGA-IGC Presidential Plenary in November 2026; FDA discussions initiated for registrational path.","REC-7735 IND cleared; Phase 1/2 ZINNIA trial for PIK3CA H1047R-mutant solid tumors to start in 2H26.","Revenue was $7.7M in Q2 2026, down from $19.2M in Q2 2025; net loss improved to $131.0M from $171.9M.","Cash operating expense guidance reduced to <$375M for 2026; cash runway extends into early 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-26-000097","json":"https://secwatch.observer/filing/0001601830-26-000097.json","markdown":"https://secwatch.observer/filing/0001601830-26-000097.md","text":"https://secwatch.observer/filing/0001601830-26-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/0001601830-26-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000097/rxrx-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T10:35:51.729472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}